Share on facebook
Share on twitter
Share on linkedin
Share on telegram
Share on whatsapp

1.2 Million Reports of Injuries After COVID Vaccines, VAERS Data Show

Share on facebook
Share on twitter
Share on telegram
Share on email
Share on print

VAERS data released Friday by the Centers for Disease Control and Prevention included a total of 1,247,131 reports of adverse events from all age groups following COVID-19 vaccines, including 27,532 deaths and 224,766 serious injuries between Dec. 14, 2020, and April 22, 2022.

The Centers for Disease Control and Prevention (CDC) today released new data showing a total of 1,247,131 reports of adverse events following COVID-19 vaccines were submitted between Dec. 14, 2020, and April 22, 2022, to the Vaccine Adverse Event Reporting System (VAERS). VAERS is the primary government-funded system for reporting adverse vaccine reactions in the U.S.

The data included a total of 27,532 reports of deaths — an increase of 183 over the previous week — and 224,766 serious injuries, including deaths, during the same time period — up 1,930 compared with the previous week.

Excluding “foreign reports” to VAERS, 810,171 adverse events, including 12,672 deaths and 80,743 serious injuries, were reported in the U.S. between Dec. 14, 2020, and April 22, 2022.

Foreign reports are reports foreign subsidiaries send to U.S. vaccine manufacturers. Under U.S. Food and Drug Administration (FDA) regulations, if a manufacturer is notified of a foreign case report that describes an event that is both serious and does not appear on the product’s labeling, the manufacturer is required to submit the report to VAERS.

Of the 12,672 U.S. deaths reported as of April 22, 16% occurred within 24 hours of vaccination, 20% occurred within 48 hours of vaccination and 59% occurred in people who experienced an onset of symptoms within 48 hours of being vaccinated.

In the U.S., 572 million COVID-19 vaccine doses had been administered as of April 23, including 338 million doses of Pfizer, 215 million doses of Moderna and 19 million doses of Johnson & Johnson (J&J).

Every Friday, VAERS publishes vaccine injury reports received as of a specified date. Reports submitted to VAERS require further investigation before a causal relationship can be confirmed.

Historically, VAERS has been shown to report only 1% of actual vaccine adverse events.

U.S. VAERS data from Dec. 14, 2020, to April 22, 2022, for 5- to 11-year-olds show:
U.S. VAERS data from Dec. 14, 2020, to April 22, 2022, for 12- to 17-year-olds show:
  • 31,455 adverse events, including 1,803 rated as serious and 44 reported deaths.The most recent reported death involves a 14-year-old girl from Tennessee (VAERS I.D. 2238618) who died after receiving her second dose of Pfizer’s COVID-19 vaccine. According to the VAERS report, the girl had a previous history of cancer but was hospitalized 29 days after receiving her second dose of Pfizer with severe COVID-19 and COVID pneumonia. She became “critically ill,” developed respiratory failure and bradycardia and later died.
  • 65 reports of anaphylaxis among 12- to 17-year-olds where the reaction was life-threatening, required treatment or resulted in death — with 96% of cases attributed to Pfizer’s vaccine.
  • 649 reports of myocarditis and pericarditis — two fewer than last week — with 637 cases attributed to Pfizer’s vaccine.
  • 165 reports of blood clotting disorders — 1 fewer than last week — with all cases attributed to Pfizer.
U.S. VAERS data from Dec. 14, 2020, to April 22, 2022, for all age groups combined, show:
FDA to meet in June on COVID-19 vaccines for babies, toddlers

The FDA will meet in June — either June 8, 21 or 22 — to discuss COVID-19 vaccines for children under age 6. The agency’s vaccine advisory committee during its June meeting will also discuss Novavax’s request for Emergency Use Authorization (EUA) of its COVID-19 vaccine for adults.

Moderna on Thursday asked the FDA to authorize its COVID-19 vaccine for emergency use for children ages 6 months to 6 years.

The company conducted separate trials for two versions of the vaccine, one for infants and toddlers 6 months to 2 years, and one for children 2 to 6 years old.

The company claimed data showed “a robust neutralizing antibody response” and “a favorable safety profile.” But experts say Moderna is not providing the data needed to calculate the risk-benefit of its COVID vaccine.

Moderna’s KidCOVE study cited in Thursday’s press release shows the Moderna shot failed to meet the FDA’s minimum efficacy requirements for EUA in the 2- to under-6 age group, and barely surpassed the agency’s 50% efficacy requirement in the 6-month to 2-year age group after the vaccine maker changed its analysis of the study to meet the threshold. .. Read More (CHD)

Subscribe
Notify of
guest
0 Comments
Inline Feedbacks
View all comments
0
Would love your thoughts, please comment.x
()
x

Get in Touch!

Purpose of your Contact
Where can i reach you?
What would you like to discuss?
[crypto-donation-box]

Are you intending to visit the Lorphic marketing agency?